Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2018 1
2019 8
2020 15
2021 3
2022 9
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS, Banerjee K, Mujeeb AA, Mauser A, Taher A, Thalla R, McClellan BL, Varela ML, Stamatovic SM, Martinez-Revollar G, Andjelkovic AV, Gregory JV, Kadiyala P, Calinescu A, Jiménez JA, Apfelbaum AA, Lawlor ER, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Sun Y, Gan J, Ackermann R, Schwendeman A, Candolfi M, Olin MR, Lahann J, Lowenstein PR, Castro MG. Alghamri MS, et al. ACS Nano. 2022 Jun 28;16(6):8729-8750. doi: 10.1021/acsnano.1c07492. Epub 2022 May 26. ACS Nano. 2022. PMID: 35616289 Free PMC article.
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
Haase S, Banerjee K, Mujeeb AA, Hartlage CS, Núñez FM, Núñez FJ, Alghamri MS, Kadiyala P, Carney S, Barissi MN, Taher AW, Brumley EK, Thompson S, Dreyer JT, Alindogan CT, Garcia-Fabiani MB, Comba A, Venneti S, Ravikumar V, Koschmann C, Carcaboso ÁM, Vinci M, Rao A, Yu JS, Lowenstein PR, Castro MG. Haase S, et al. J Clin Invest. 2022 Nov 15;132(22):e154229. doi: 10.1172/JCI154229. J Clin Invest. 2022. PMID: 36125896 Free PMC article.
Engineering patient-specific cancer immunotherapies.
Scheetz L, Park KS, Li Q, Lowenstein PR, Castro MG, Schwendeman A, Moon JJ. Scheetz L, et al. Nat Biomed Eng. 2019 Oct;3(10):768-782. doi: 10.1038/s41551-019-0436-x. Epub 2019 Aug 12. Nat Biomed Eng. 2019. PMID: 31406259 Free PMC article. Review.
Prospects of biological and synthetic pharmacotherapies for glioblastoma.
Altshuler DB, Kadiyala P, Nuñez FJ, Nuñez FM, Carney S, Alghamri MS, Garcia-Fabiani MB, Asad AS, Nicola Candia AJ, Candolfi M, Lahann J, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Altshuler DB, et al. Expert Opin Biol Ther. 2020 Mar;20(3):305-317. doi: 10.1080/14712598.2020.1713085. Epub 2020 Jan 20. Expert Opin Biol Ther. 2020. PMID: 31959027 Free PMC article. Review.
Mutant ATRX: uncovering a new therapeutic target for glioma.
Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, Núñez FJ, Méndez FM, Núñez F, Lowenstein PR, Castro MG. Haase S, et al. Expert Opin Ther Targets. 2018 Jul;22(7):599-613. doi: 10.1080/14728222.2018.1487953. Epub 2018 Jun 20. Expert Opin Ther Targets. 2018. PMID: 29889582 Free PMC article. Review.
41 results